PARP1 and breast cancer: PARP inhibitors (polyADP-ribose polymerases) such as Olaparib and Talazoparib have been approved by the Food and Drug Administration (FDA) for metastatic BC and germline BRCA mutation, while Niraparib, Rucaparib, and Veliparib are undergoing clinical trials [54].